Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

LEUVEN, Belgium, December 4 /PRNewswire/ --

- Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for Vitrectomy

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular and eye diseases, will today present results from its Phase IIa MIVI IIT trial at the American Society of Retina Specialists (ASRS) 25th Annual Meeting in Indian Wells, California. The trial, which delivered positive clinical results in a number of the treated patients, was designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, an important cause of back of the eye disease. The results of the study will be presented by Professor Peter Stalmans, University Hospitals, Leuven, Belgium.

Vitreomacular traction is a condition where the vitreous (the central fluid part of the eye) has an abnormally strong adhesion to the surface of the macula (the part of the retina responsible for detailed vision). Due to this, the macula may become distorted creating poor or deficient vision. Vitreomacular traction can also lead to sight threatening conditions such as macular holes or macular edema.

In current practice, these conditions are treated by a highly skilled surgical procedure called vitrectomy. The procedure uses suction to remove the vitreous from the eye to induce posterior vitreous detachment or PVD, thereby alleviating the vitreomacular traction. The potential use of microplasmin to treat vitreomacular traction could therefore provide a more convenient, much less invasive approach, to both patients and physicians, for the treatment of important back of the eye diseases such as macular holes, diabetic macular edema, diabetic retinopathy in general, and even in age related macular degeneration (AMD), which are caused or exacerbated by the vitreous adhering to the retina abnormally.

The Phase IIa MIVI-IIT trial reported today was a sham injection controlled study in which patients were assigned to receive either 75ug or 125ug of microplasmin. A total of 30 patients across Europe were recruited to the study, of which 24 received microplasmin therapy while 6 received the sham injection. The trial showed clear benefits from therapy with 9 of the 24 microplasmin treated patients seeing resolution of their vitreomacular traction (including macular hole closure in 2 of the 4 macular hole cases) without the need for vitrectomy. In contrast, none of the 6 sham injected patients had resolution of their vitreomacular traction (including two patients with macular hole). The trial also showed that microplasmin therapy was safe and well tolerated. Given the excellent safety of microplasmin in the trial to-date, it has been decided to recruit a further 15 patients (12 treated and 3 sham) to evaluate a higher 175ug dose of the product to see if it will produce even better clinical outcomes.

Professor Peter Stalmans, the study's principal investigator, commented: "The results from the study that I will present at the ASRS meeting today clearly indicate the potential for microplasmin to become a more convenient, less invasive, hence more patient friendly treatment for vitreomacular traction. The fact that we have been able to clearly show that microplasmin can achieve clinically important outcomes such as traction release and macular hole closure without surgery augurs well for the future development of this novel treatment."

Prof. Desire Collen, CEO of ThromboGenics, commenting on today's results said: "The results of the microplasmin trial that we have announced today clearly show the drug's potential to treat a range of back of the eye diseases. The clinical benefits that we have seen in this study in conjunction with its excellent safety profile provide us with sound reasons for pushing ahead with the further clinical development of microplasmin."

About Vitreomacular Traction

Numerous conditions are associated with vitreomacular traction which may lead to decreased vision and/or complications. These include macular hole, macular edema (ME) associated with vitreomacular traction, and vitreomacular traction syndrome (VTMS). The only available treatment for these conditions is surgical vitrectomy, in order to induce a posterior vitreous detachment (PVD) and thereby alleviate the vitreomacular traction. Therefore, a pharmacological agent that could relieve vitreomacular traction nonsurgically would be a dramatic advance for the treatment of these conditions, preventing the need for surgery and its associated cost, inconvenience and risk of complications. Macular hole prevalence is approximately 0.14% of general population, leading to estimates of approximately 400,000 cases in the US and of up to 1 million in the industrialized world.

Other potential nonsurgical applications for microplasmin include treatment of macular edema and diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness among working-age adults while diabetic macular edema (DME) is the leading cause of decreased vision in patients with diabetic retinopathy. Around 750,000 patients suffer from DME in the United States alone.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular and eye diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Prof. Desire Collen, CEO

Dr. Patrik De Haes, COO

Tel: +32(0)16-34-61-94

Citigate Dewe Rogerson

Valerie Auffray / David Dible / Amber Bielecka

Tel: +44(0)207-638-95-71

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):